A carregar...
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal cancer (CRC). Through genetic screens, we unexpectedly find that mutant HRAS, which is rarely found in CRC, is a stronger driver of resistance than mutant KRAS. This difference is ascribed to common codon...
Na minha lista:
| Publicado no: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5472712/ https://ncbi.nlm.nih.gov/pubmed/28593995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms15617 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|